By Colin Kellaher
Merck & Co. on Wednesday said a phase 3 study of its cancer drug Keytruda in combination with chemotherapy met one of its dual primary endpoints in a form of triple-negative breast cancer.
The Kenilworth, N.J., drug maker said the combination showed a statistically significant and clinically meaningful improvement in progression-free survival in patients with metastatic triple-negative breast cancer whose tumors expressed PD-L1.
Merck said the study will continue without changes to evaluate the other primary endpoint of overall survival.
The company said Keytruda's safety profile in the trial was consistent with previous studies, with no new safety signals identified.
Write to Colin Kellaher at email@example.com